IgA nephropathy trials in Slovakia

2 of 2 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

• Phase 3Active, not recruiting
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Košice

  Age

  18 years to 100 years

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• Early phase 1Enrolling by invitation
  The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.

  Where

  Martin

  Age

  18 years and over

  People

  120

  Run by

  University Hospital, Martin

  See details and how to joinNCT07750249